Studies in these directions, identification of heparanase receptor(s) mediating its signaling function, and elucidation of heparanase route and function in the cell nucleus, will advance the field of heparanase research and reveal its significance in license with Pfizer health and disease. While most attention was paid in recent years to heparanase function in tumor biology, emerging evidence indicates that heparanase is also engaged in several other pathological disorders.

A most interesting example is the apparent role Inhibitors,research,lifescience,medical of heparanase in glomerular diseases.103 HSPGs are important constituents of the glomerular basement membrane (GBM) and its permselective properties.11 Loss of HSPGs was observed in several experimental and human glomerulopathies, including diabetic nephropathy, Inhibitors,research,lifescience,medical minimal change disease, and membranous glomerulophathy. In addition, expression of heparanase was up-regulated in the course of these diseases,104 likely destructing Inhibitors,research,lifescience,medical the permselective properties of HS. Notably, PI-88 (a heparanase inhibitor) was effective as an antiproteinuric drug in an experimental model.105 Heparanase is also causally selleckbio associated with inflammatory conditions such as inflammatory bowel disease61 and rheumatoid

arthritis,62 among other inflammatory conditions (Lerner et al., our unpublished results). Novel heparanase inhibitors such as glycol-split heparin or more advanced oligosaccharide-based compounds48 are hoped to enter the clinic and provide relief in diabetic, colitis, and cancer patients’ condition. Resolving the heparanase Inhibitors,research,lifescience,medical crystal structure will accelerate the development of effective inhibitory

molecules and neutralizing antibodies, Inhibitors,research,lifescience,medical paving the way for advanced clinical trials in patients with cancer and other diseases involving heparanase. Acknowledgments We thank Professor Benito Casu (“Ronzoni” Institute, Milan, Italy) and Professor Ralph Sanderson (University of Alabama at Birmingham) for their continuous support and active collaboration. This work was supported by grants from the Israel Science Foundation (593/10); National Cancer Institute, NIH (RO1-CA106456); the Israel Cancer Research Fund AV-951 (ICRF); and the Ministry of Science & Technology of the State of Israel and the German Cancer Research Center (DKFZ). I. Vlodavsky is a Research Professor of the ICRF. We gratefully acknowledge the contribution, motivation, and assistance of the research teams in the Hadassah-Hebrew University Medical Center (Jerusalem, Israel) and the Cancer and Vascular Biology Research Center of the Rappaport Faculty of Medicine (Technion, Haifa).